5dxu

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (12:26, 6 March 2024) (edit) (undo)
 
(2 intermediate revisions not shown.)
Line 1: Line 1:
==p110delta/p85alpha with GDC-0326==
==p110delta/p85alpha with GDC-0326==
-
<StructureSection load='5dxu' size='340' side='right' caption='[[5dxu]], [[Resolution|resolution]] 2.64&Aring;' scene=''>
+
<StructureSection load='5dxu' size='340' side='right'caption='[[5dxu]], [[Resolution|resolution]] 2.64&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>[[5dxu]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5DXU OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5DXU FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[5dxu]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Bos_taurus Bos taurus] and [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5DXU OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5DXU FirstGlance]. <br>
-
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=5H5:(2S)-2-({2-[1-(PROPAN-2-YL)-1H-1,2,4-TRIAZOL-5-YL]-5,6-DIHYDROIMIDAZO[1,2-D][1,4]BENZOXAZEPIN-9-YL}OXY)PROPANAMIDE'>5H5</scene></td></tr>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.64&#8491;</td></tr>
-
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5dxh|5dxh]], [[5dxt|5dxt]]</td></tr>
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=5H5:(2S)-2-({2-[1-(PROPAN-2-YL)-1H-1,2,4-TRIAZOL-5-YL]-5,6-DIHYDROIMIDAZO[1,2-D][1,4]BENZOXAZEPIN-9-YL}OXY)PROPANAMIDE'>5H5</scene></td></tr>
-
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Phosphatidylinositol-4,5-bisphosphate_3-kinase Phosphatidylinositol-4,5-bisphosphate 3-kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.153 2.7.1.153] </span></td></tr>
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5dxu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5dxu OCA], [https://pdbe.org/5dxu PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5dxu RCSB], [https://www.ebi.ac.uk/pdbsum/5dxu PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5dxu ProSAT]</span></td></tr>
-
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5dxu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5dxu OCA], [http://pdbe.org/5dxu PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5dxu RCSB], [http://www.ebi.ac.uk/pdbsum/5dxu PDBsum]</span></td></tr>
+
</table>
</table>
== Disease ==
== Disease ==
-
[[http://www.uniprot.org/uniprot/PK3CD_HUMAN PK3CD_HUMAN]] Activated PIK3-delta syndrome. The disease is caused by mutations affecting the gene represented in this entry.
+
[https://www.uniprot.org/uniprot/PK3CD_HUMAN PK3CD_HUMAN] Activated PIK3-delta syndrome. The disease is caused by mutations affecting the gene represented in this entry.
== Function ==
== Function ==
-
[[http://www.uniprot.org/uniprot/PK3CD_HUMAN PK3CD_HUMAN]] Phosphoinositide-3-kinase (PI3K) that phosphorylates PftdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Mediates immune responses. Plays a role in B-cell development, proliferation, migration, and function. Required for B-cell receptor (BCR) signaling. Mediates B-cell proliferation response to anti-IgM, anti-CD40 and IL4 stimulation. Promotes cytokine production in response to TLR4 and TLR9. Required for antibody class switch mediated by TLR9. Involved in the antigen presentation function of B-cells. Involved in B-cell chemotaxis in response to CXCL13 and sphingosine 1-phosphate (S1P). Required for proliferation, signaling and cytokine production of naive, effector and memory T-cells. Required for T-cell receptor (TCR) signaling. Mediates TCR signaling events at the immune synapse. Activation by TCR leads to antigen-dependent memory T-cell migration and retention to antigenic tissues. Together with PIK3CG participates in T-cell development. Contributes to T-helper cell expansion and differentiation. Required for T-cell migration mediated by homing receptors SELL/CD62L, CCR7 and S1PR1 and antigen dependent recruitment of T-cells. Together with PIK3CG is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in NK cell receptor activation. Have a role in NK cell maturation and cytokine production. Together with PIK3CG is involved in neutrophil chemotaxis and extravasation. Together with PIK3CG participates in neutrophil respiratory burst. Have important roles in mast-cell development and mast cell mediated allergic response. Involved in stem cell factor (SCF)-mediated proliferation, adhesion and migration. Required for allergen-IgE-induced degranulation and cytokine release. The lipid kinase activity is required for its biological function. Isoform 2 may be involved in stabilizing total RAS levels, resulting in increased ERK phosphorylation and increased PI3K activity.<ref>PMID:20081091</ref> <ref>PMID:22020336</ref> [[http://www.uniprot.org/uniprot/P85A_BOVIN P85A_BOVIN]] Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling (By similarity).
+
[https://www.uniprot.org/uniprot/PK3CD_HUMAN PK3CD_HUMAN] Phosphoinositide-3-kinase (PI3K) that phosphorylates PftdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Mediates immune responses. Plays a role in B-cell development, proliferation, migration, and function. Required for B-cell receptor (BCR) signaling. Mediates B-cell proliferation response to anti-IgM, anti-CD40 and IL4 stimulation. Promotes cytokine production in response to TLR4 and TLR9. Required for antibody class switch mediated by TLR9. Involved in the antigen presentation function of B-cells. Involved in B-cell chemotaxis in response to CXCL13 and sphingosine 1-phosphate (S1P). Required for proliferation, signaling and cytokine production of naive, effector and memory T-cells. Required for T-cell receptor (TCR) signaling. Mediates TCR signaling events at the immune synapse. Activation by TCR leads to antigen-dependent memory T-cell migration and retention to antigenic tissues. Together with PIK3CG participates in T-cell development. Contributes to T-helper cell expansion and differentiation. Required for T-cell migration mediated by homing receptors SELL/CD62L, CCR7 and S1PR1 and antigen dependent recruitment of T-cells. Together with PIK3CG is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in NK cell receptor activation. Have a role in NK cell maturation and cytokine production. Together with PIK3CG is involved in neutrophil chemotaxis and extravasation. Together with PIK3CG participates in neutrophil respiratory burst. Have important roles in mast-cell development and mast cell mediated allergic response. Involved in stem cell factor (SCF)-mediated proliferation, adhesion and migration. Required for allergen-IgE-induced degranulation and cytokine release. The lipid kinase activity is required for its biological function. Isoform 2 may be involved in stabilizing total RAS levels, resulting in increased ERK phosphorylation and increased PI3K activity.<ref>PMID:20081091</ref> <ref>PMID:22020336</ref>
-
<div style="background-color:#fffaf0;">
+
-
== Publication Abstract from PubMed ==
+
-
Inhibitors of the class I phosphoinositide 3-kinase (PI3K) isoform PI3Kalpha have received substantial attention for their potential use in cancer therapy. Despite the particular attraction of targeting PI3Kalpha, achieving selectivity for the inhibition of this isoform has proved challenging. Herein we report the discovery of inhibitors of PI3Kalpha that have selectivity over the other class I isoforms and all other kinases tested. In GDC-0032 (3, taselisib), we previously minimized inhibition of PI3Kbeta relative to the other class I insoforms. Subsequently, we extended our efforts to identify PI3Kalpha-specific inhibitors using PI3Kalpha crystal structures to inform the design of benzoxazepin inhibitors with selectivity for PI3Kalpha through interactions with a nonconserved residue. Several molecules selective for PI3Kalpha relative to the other class I isoforms, as well as other kinases, were identified. Optimization of properties related to drug metabolism then culminated in the identification of the clinical candidate GDC-0326 (4).
+
-
 
+
-
The Rational Design of Selective Benzoxazepin Inhibitors of the alpha-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1 ,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).,Heffron TP, Heald RA, Ndubaku C, Wei B, Augistin M, Do S, Edgar K, Eigenbrot C, Friedman L, Gancia E, Jackson PS, Jones G, Kolesnikov A, Lee LB, Lesnick JD, Lewis C, McLean N, Mortl M, Nonomiya J, Pang J, Price S, Prior WW, Salphati L, Sideris S, Staben ST, Steinbacher S, Tsui V, Wallin J, Sampath D, Olivero AG J Med Chem. 2016 Jan 20. PMID:26741947<ref>PMID:26741947</ref>
+
-
 
+
-
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
+
-
</div>
+
-
<div class="pdbe-citations 5dxu" style="background-color:#fffaf0;"></div>
+
== References ==
== References ==
<references/>
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
-
[[Category: Phosphatidylinositol-4,5-bisphosphate 3-kinase]]
+
[[Category: Bos taurus]]
-
[[Category: Augustin, M]]
+
[[Category: Homo sapiens]]
-
[[Category: Do, S]]
+
[[Category: Large Structures]]
-
[[Category: Edgar, K]]
+
[[Category: Augustin M]]
-
[[Category: Eigenbrot, C]]
+
[[Category: Do S]]
-
[[Category: Friedman, L]]
+
[[Category: Edgar K]]
-
[[Category: Gancia, E]]
+
[[Category: Eigenbrot C]]
-
[[Category: Heald, R A]]
+
[[Category: Friedman L]]
-
[[Category: Heffron, T P]]
+
[[Category: Gancia E]]
-
[[Category: Jackson, P S]]
+
[[Category: Heald RA]]
-
[[Category: Jones, G]]
+
[[Category: Heffron TP]]
-
[[Category: Kolesnikov, A]]
+
[[Category: Jackson PS]]
-
[[Category: Lee, L B]]
+
[[Category: Jones G]]
-
[[Category: Lesnick, J D]]
+
[[Category: Kolesnikov A]]
-
[[Category: Lewis, C]]
+
[[Category: Lee LB]]
-
[[Category: McLean, N]]
+
[[Category: Lesnick JD]]
-
[[Category: Mortle, M]]
+
[[Category: Lewis C]]
-
[[Category: Ndubaku, C]]
+
[[Category: McLean N]]
-
[[Category: Nonomiya, J]]
+
[[Category: Mortle M]]
-
[[Category: Olivero, A]]
+
[[Category: Ndubaku C]]
-
[[Category: Pang, J]]
+
[[Category: Nonomiya J]]
-
[[Category: Price, S]]
+
[[Category: Olivero A]]
-
[[Category: Prior, W W]]
+
[[Category: Pang J]]
-
[[Category: Salphati, L]]
+
[[Category: Price S]]
-
[[Category: Sampath, D]]
+
[[Category: Prior WW]]
-
[[Category: Sideris, S]]
+
[[Category: Salphati L]]
-
[[Category: Staben, S T]]
+
[[Category: Sampath D]]
-
[[Category: Steinbacher, S]]
+
[[Category: Sideris S]]
-
[[Category: Tsui, V]]
+
[[Category: Staben ST]]
-
[[Category: Wallin, J]]
+
[[Category: Steinbacher S]]
-
[[Category: Wei, B Q]]
+
[[Category: Tsui V]]
-
[[Category: Inhibitor]]
+
[[Category: Wallin J]]
-
[[Category: Lipid kinase]]
+
[[Category: Wei BQ]]
-
[[Category: Transferase-inhibitor complex]]
+

Current revision

p110delta/p85alpha with GDC-0326

PDB ID 5dxu

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools